Binliang A. Liu
No. 283, Tongzipo Road, Yuelu District
Changsha, 410013, China
Changsha, 410013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study.
Journal: Breast cancer research and treatment
Published: March 15, 2026
Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression.
Journal: NPJ breast cancer
Published: December 10, 2025
Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: June 28, 2025
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study.
Journal: Breast (Edinburgh, Scotland)
Published: March 19, 2025
Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.
Journal: The oncologist
Published: February 22, 2025
Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study.
Journal: Cardio-oncology (London, England)
Published: February 06, 2025
Interpretable Machine Learning Algorithms Identify Inetetamab-Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer.
Journal: Journal of clinical laboratory analysis
Published: June 01, 2024
Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer.
Journal: Cancer innovation
Published: April 11, 2024
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.
Journal: Breast (Edinburgh, Scotland)
Published: September 21, 2023
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.
Journal: BMC cancer
Published: September 20, 2023
Breast cancer metastases to the thyroid and stomach: A case report.
Journal: Oncology letters
Published: January 30, 2023
Last Updated: 09/26/2026